Omicron Pharma
  • Home
  • Products
    • Women’s Health
      • Women Infertility
      • Pregnancy
      • Bone Health
      • Anemia
      • Vaginal Health
    • Men’s Health
      • Male Infertility
    • Cardiovascular Health
    • Weight Management
      • Weight Reduction
      • Reshaping
      • Appetite Control
    • Skin Health
      • Wounds & Burns
    • Pediatric Health
    • Respiratory Health
  • Literature
  • Careers
  • About us
  • Contact us
Select Page
MenaCAL/D3®

MenaCAL/D3®

Ovaforte®

Ovaforte®

Actifol®

Actifol®

Low-dose menaquinone-7 supplementation improved extra-hepatic vitamin K status, but had no effect on thrombin generation in healthy subjects

Low-dose menaquinone-7 supplementation improved extra-hepatic vitamin K status, but had no effect on thrombin generation in healthy subjects

Vitamin K is required for the carboxylation of Gla-proteins in the liver (coagulation factors) and extra-hepatic tissues, such as bone (osteo- calcin, OC), and arterial wall (matrix Gla-protein, MGP). Although the coagulation factors are essentially fully carboxylated...
Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women

Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women

Summary We have investigated whether low-dose vitamin K2 supplements (menaquinone-7, MK-7) could beneficially affect bone health. Next, to an improved vitamin K status, MK-7 supplementation significantly decreased the age- related decline in bone mineral density and...
« Older Entries
Next Entries »

Recent Posts

  • Cold & Cough®
  • Chewie Bone®
  • Hyperoil®
  • Lypotrol®
  • Cenitrol®

Recent Comments

  1. A WordPress Commenter on High Dephosphorylated-Uncarboxylated MGP in Hemodialysis patients: risk factors and response to vitamin K2, A pre-post intervention clinical trial


Phone

+961 5 922 831



Email

info@omicron-pharma.com

Subscribe For Updates

Success!

Subscribe

  • Follow
  • Follow
  • Follow